The new ICD-10-CM codes for FY 2018, effective October 1, represent significant changes in our documentation and coding practices. Let’s discuss some of these new codes and their potential impact upon your diagnostic decision-making and documentation.
Providers in some states may soon discover a big hurdle to clear when seeking to report a set of apheresis services after one MAC tightened up physician supervision requirements.
In the 2018 OPPS proposed rule, CMS proposed a change to the current clinical laboratory date-of-service policies for molecular pathology tests and for Advanced Diagnostic Laboratory Tests.
One of the reasons that we all read Briefings in Coding Compliance Strategies is to maintain our competence and quality in coding and risk-adjustment principles as to anticipate how recovery auditors and accountability agents view our coded data. While a good compliance officer and attorney knows the law, the better one knows the law, the judge, and the jury.
The fiscal year (FY) 2018 IPPS final rule includes updates to payment rates and quality initiatives, but some of the most extensive changes pertain to MS-DRG classifications and relative weights.
You may be thinking that you’ve never heard of scleroderma. As a coder, we know to look at these big fancy words and break them down by their root words in order to get a clue of what we’re talking about.
CMS recently released the fiscal year (FY) 2018 IPPS final rule which featured updates to various quality initiatives, along with annual payment updates for inpatient services.
In Major Diagnostic Category 1, Diseases and Disorders of the Nervous System, which covers MS-DRGs 020-103, CMS made changes to the classification of the diagnoses of functional quadriplegia and precerebral occlusion or transient ischemic attack with the use of a thrombolytic, as well as for the insertion of a responsive neurostimulator system. Note: To access this free article, make sure you first register here if you do not have a paid subscription.
